The intra-articular injection of hydrocortisone acetate is commonly used in the treatment of osteoarthritis, although its action in this disease has received less careful study than in rheumatoid arthritis. In 1955 a less soluble ester, hydrocortisone tertiary-butylacetate (TBA) was developed for intraarticular therapy with the claim that its effects were more pronounced and of longer duration (Hollander, Brown, Jessar, Udell, Smukler, and Bowie, 1955 The fortnightly assessments comprised the following measurements:
The intra-articular injection of hydrocortisone acetate is commonly used in the treatment of osteoarthritis, although its action in this disease has received less careful study than in rheumatoid arthritis. In 1955 a less soluble ester, hydrocortisone tertiary-butylacetate (TBA) was developed for intraarticular therapy with the claim that its effects were more pronounced and of longer duration (Hollander, Brown, Jessar, Udell, Smukler, and Bowie, 1955) .
The purpose of the present trial was to evaluate both drugs in the treatment of osteo-arthritis by a double-blind, crossover method. Each patient received both compounds as well as placebo and thus served as his own control. This formed part of a wider study of the value of intra-articular therapy in rheumatic disease. The results of the present investigation will be compared with those obtained in rheumatoid arthritis (Chandler, Wright, and Hartfall, 1958 ).
Design of Trial 25 patients whose main complaint arose from osteo-a'rthritis of the knees were included in the trial. In thirteen both knees were treated, and in twelve only one knee, giving a total of 38 joints suitable for trial. No patient had received intraarticular therapy within 2 months of the start of the trial. Symptomatic treatment remained constant throughout the period of study which was conducted under out-patient conditions.
The The fortnightly assessments comprised the following measurements:
Walking time over 75 yards; Range ofjoint movement and limitation of extension determined by a goniometer; Tenderness (graded 0 = none, 1 = slight, 2 = definite, 3 = wincing, 4 = withdrawal and/or exclamation); Pain (graded 0 = none, 1 = slight on walking, 2 = marked on walking, 3 = mild at rest, 4 = severe at rest).
Radiographs of the knees were obtained before and after the trial.
Results
Three patients failed to complete the trial; two defaulted after the second course of injections, and one developed an unrelated disease after the third injection of the second course. This resulted in five knees not receiving a course ofplacebo injections.
The specific data (walking time, etc.) derived from the first assessment in each treatment period were compared with the same measurements made at the four assessments in the succeeding 8-week rest period. Changes in walking time and joint movement were estimated as a percentage of the pretreatment measurements; changes in limitation of extension were calculated as a percentage of maximal joint range (145°). Although pain and tenderness were graded at each assessment, because this parameter is entirely subjective, differences were calculated on the basis of improvement and no improvement. In this way the effect of treatment, both immediate and sustained, was calculated for each knee for each of the three treatments. The mean change for each of the three groups (hydrocortisone, TBA, and placebo) between pre-treatment assessments and each of the four post-treatment assessments was analysed by conventional statistical methods.
Pain.-At the second week after the course of injections a greater proportion of the knees receiving hydrocortisone and TBA improved than did those receiving the placebo (Table I ). The response to TBA was significantly better than that to the placebo (P <002), but the greater improvement following hydrocortisone when compared with placebo did not achieve the level of significance (P <0 3). There was no significant difference between the response to the two active drugs (P <02). At subsequent assessments there was no significant difference between the response to any of the injections.
Other Parameters.-No significant improvement in walking time, range of movement, limitation of extension, or tenderness was apparent after the injection of the two drugs compared with placebo.
Advantage of First Treatment
It has been suggested that, irrespective of the nature of the substance injected, the first course of injections given to a patient with rheumatoid arthritis will produce subjective improvement (Fearnley, Lackner, Meanock, and Bywaters, 1956 ). This possibility was therefore studied by comparing the improvement following the first course of injections with that following the second and third courses which were grouped together for purposes of analysis (Table II) . Only with walking time did the first course of treatment show a significant advantage over subsequent treatments. Here the difference was very striking. The mean improvement after the first course was 9 per cent. compared with 1 per cent. after subsequent courses. The difference is highly significant (P <0-01).
The improvement 2 weeks after the first injection of the first course was then compared with the improvement 2 weeks after the second injection of that course. There was no significant difference between the effect of the first and the second injection.
Complications
In two knees there was increased pain and stiffness lasting 2 and 3 days respectively after the injection of TBA. One patient complained of swelling of the ankle on two occasions after the injection of TBA, but no abnormality was seen at his next visit to the clinic.
Radiological Changes
Radiographs of each injected knee (anteroposterior and lateral) were taken at the beginning and end of the trial. The x-ray appearances were graded into four categories for osteo-arthritis (Kellgren and Lawrence, (Hollander and others, 1951; Duff, 1956; Zuckner, Machek, and Ahern, 1956; Bonner, 1959) . In a strictly controlled study (Chandler, Wright, and Hartfall, 1958) , it was demonstrated that both hydrocortisone acetate and its tertiary-butylacetate derivative had a significant advantage over a placebo in the treatment of the knees of patients with rheumatoid arthritis. Improvement was generally greater and of longer duration with TBA than with hydrocortisone, but the difference was not significant.
Even greater value has been claimed for both these agents in osteo-arthritis (Hollander and others, 1951;  Desmarais, 1952; Hollander and others, 1955; Zuckner, Machek, Caciolo, Ahern, and Ramsey, 1958) . Williams (1958) claimed that TBA was effective over a longer period than hydrocortisone, but Kehr (1959) could detect no difference.
In the present study the response to treatment with respect to pain and tenderness has been classed as improved or not improved.
It was felt that to apply statistical methods to numbers assigned for grades of pain and tenderness would be merely to cover an edifice of inaccuracy with a coat of scientific paint. On these criteria the only significant improvement obtained from the active compounds was that in respect of pain; 2 weeks after the injection of both drugs less pain was experienced than after the placebo, and this was statistically significant (P <0 02) in the case of TBA. There was no significant difference between the active drugs. At the fourth and subsequent weeks after injection, however, neither drug conferred any significant advantage over the placebo. The effect of TBA although significant was transient. The fact that the improvement following hydrocortisone was not significant at the second week suggests that its effect is even more short lived than that of TBA.
The benefit derived from these drugs was therefore much less marked than that previously obtained under similar conditions in patients with rheumatoid arthritis who improved in all criteria of assessment for periods of 2 to 8 weeks. Nor do our findings accord with the majority experience (Hollander and others, 1951; Desmarais, 1952; Williams, 1958; Kehr, 1959 ); yet the results are not unexpected in view of the fundamentally different pathology of the two diseases. It is to be anticipated that the inflammatory arthritis of rheumatoid type would show a better response to steroid therapy, either local or systemic, than the purely degenerative lesion of osteo-arthritis. The difference between our experience and that of others in the local treatment of osteo-arthritis may reflect only the failure of other authors to conduct trials under controlled conditions. Miller, White, and Norton (1958) , in a careful study of 181 patients with osteo-arthritis of the knees, were unable to detect any difference in response to the injection of lactic acid, novocaine, hydrocortisone, and saline. However, the first assessment following treatment was made 6 weeks after the course of injections, so that a less prolonged effect could not be measured.
Effect of Order of Injection. -Fearnley and others (1956) , in a pilot study of intra-articular procaine and hydrocortisone acetate in rheumatoid arthritis, found that the first course of treatment conferred more benefit than the second, regardless of which drug was used. In this study of patients with osteo-arthritis this was evident in the effect on walking time. The percentage improvement in walking time after the first course was nine times greater than that after subsequent courses. Claims for improvement from single courses of treatment must therefore be evaluated cautiously in the light of this observation.
Placebo Response.-It was of interest that, although more patients experienced relief of pain after injection of the active compounds than after that of the placebo, in 36 per cent. of knees there was improvement from the inert material. If one-third improves with inactive material, great care must obviously be exercised in interpreting the results of uncontrolled studies of intra-articular therapy. The interesting problem of the placebo reactor has formed the basis of a further study of these patients by Morison, Woodmansey, and Young (1960 Cada enfermo recibi6, en un orden determinado al azar, tres series de inyecciones: hidrocortisona, TBA y una substancia inerte de control. Cada serie consisti6 en cuatro inyecciones quincenales, con ocho semanas de descanso entre las series. Cada quincena se investig6: dolor espontineo, dolor provocado a la exploarcion, tiempo caminando, amplitud del movimiento articular y limitacion de la extension.
Una pasajera disminucion del dolor siguio a cada serie de inyecciones de compuesto activo, pero no se apreci6 otro beneficio significative. No se not6 diferencia apreciable entre los efectos de los dos compuestos de hidrocortisona. Una apreciable mejoria del "tiempo caminando" apareci6 despues de la primera serie de inyecciones, independientemente de la substancia administrada. Tres enfermos experimentaron complicaciones minimas. No se observe agravaci6n de los signos radiol6gicos en las rodillas inyectadas.
El 36 por ciento de los enfermos aseguraron haber experimentado mejoria con la inyecci6n de substancia inerte. En una investigation posterior del efecto de comprimidos postizos en dichos enfermos, 26 por ciento de ellos manifesto una mejoria y el 38 por ciento efectos secundarios. Los enfermos que repetidamente no presentaron ninguna respuesta terapeutica a estos comprimidos de substancia inerte, tampoco presentaron efectos secundarios.
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